KEYNOTE-811: Presentation by Dr. Kai-Keen Shiu
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 04:04
Dr. Kai-Keen Shiu, Consultant Medical Oncologist at the UCL Cancer Institute, describes results from the KEYNOTE-811 trial for patients with locally advanced unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma expressing PD-L1 with CPS ≥1. 1
CPS = combined positive score; GOJ = gastro-oesophageal junction; HER2 = human epidermal growth factor receptor 2; PD-L1 = programmed death ligand 1
More information about KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic gastro-oesophageal cancer.
References
- Janjigian YY, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023 Dec 9; 402: 21970-208.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.
